218 Users Online
Umbilical Cord Blood Banking Market Segmented By Leukemia, Bone Marrow Failure Syndrome, Metabolic/Storage Diseases, Lymphoma, Immune Deficiencies Application with Private UCB Banks and Public UCB Banks Storage Option
Chapter 1. Preface
1.1. Report Description
1.2. Report Methodology
1.3. Assumptions
Chapter 2. Market Synopsis
Chapter 3. Porter’s Five Forces Analysis
3.1. Bargaining Power of Suppliers
3.2. Bargaining Power of Buyers
3.3. Threat of New Entrants
3.4. Threat of Substitutes
3.5. Intensity of Rivalry
Chapter 4. Industry overview
4.1. Market Definition
4.2. Market Drivers
4.2.1. Increasing prevalence of chronic diseases enhances the market growth
4.2.2. Emerging field of regenerative medicines boost the market growth
4.2.3. Initiatives by various government associations have increased the importance of UCB
4.3. Impact Analysis of Market Drivers
4.4. Market Restraints
4.4.1. Strict license and accreditation procedures impede the market growth
4.4.2. High cord blood banking fee in private UCB banks
4.5. Impact Analysis of Market Restraints
4.6. Market Tends
4.6.1. UCB is gaining popularity in allogeneic hematopoietic stem cell transplantation
4.6.2. Umbilical cord tissue storage is gaining importance in UCB banking market
Chapter 5. Global Market Size and Forecast
Chapter 6. Market Size and Forecast by Therapeutic Application of UCB
6.1. Leukemia
6.2. Bone Marrow Failure Syndrome
6.3. Metabolic/Storage Diseases
6.4. Lymphoma
6.5. Immune Deficiencies
Chapter 7. Market Size and Forecast by Storage Option
7.1. Private UCB Banks
7.2. Public UCB Banks
Chapter 8. Market Size and Forecast by Geography
8.1. North America
8.1.1. Scenario in the U.S.
8.1.1.1. Legislations
8.1.2. Scenario in Canada
8.2. Europe
8.2.1. Scenario in the U.K.
8.2.1.1. Legislations
8.2.2. Scenario in France
8.2.3. Scenario in the Germany
8.2.4. Scenario in Spain
8.2.5. Scenario in Italy
8.2.6. Scenario in Belgium
8.3. Asia Pacific
8.3.1. Scenario in China
8.3.2. Scenario in India
8.3.3. Scenario in Japan
8.3.4. Scenario in Australia
8.3.5. Scenario in Singapore
Chapter 9. Competitive Scenario
9.1. Competitive Benchmarking
Chapter 10. Company Profiles
10.1. Cord Blood Registry Systems, Inc.
10.1.1. Company overview
10.1.2. Products and services
10.1.3. Financial performance
10.1.4. Recent developments
10.2. Cordlife Group Limited
10.2.1. Company overview
10.2.2. Products and services
10.2.3. Financial performance
10.2.4. Recent developments
10.3. Cord Blood America, Inc.
10.3.1. Company overview
10.3.2. Products and services
10.3.3. Financial performance
10.3.4. Recent developments
10.4. NeoStem, Inc.
10.4.1. Company overview
10.4.2. Products and services
10.4.3. Financial performance
10.4.4. Recent developments
10.5. Cryo-Cell International, Inc.
10.5.1. Company overview
10.5.2. Products and services
10.5.3. Financial performance
10.5.4. Recent developments
10.6. ViaCord
10.6.1. Company overview
10.6.2. Products and services
10.6.3. Financial performance
10.6.4. Recent developments
10.7. Esperite N.V.
10.7.1. Company overview
10.7.2. Products and services
10.7.3. Financial performance
10.7.4. Recent developments
10.8. StemCyte
10.8.1. Company overview
10.8.2. Products and services
10.8.3. Financial performance
10.8.4. Recent Developments
10.9. Smart Cells International, Ltd.
10.9.1. Company overview
10.9.2. Products and services
10.9.3. Financial performance
10.9.4. Recent developments
10.10. China Cord Blood Corporation
10.10.1. Company overview
10.10.2. Products and Services
10.10.3. Financial performance
10.10.4. Recent developments
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
List of Tables
TABLE 1: Market Snapshot: Global market for UCB banking (2014 and 2020)
TABLE 2: Application of UCB in disease treatment
TABLE 3: Drivers for UCB banking market: Impact analysis
TABLE 4: Restraints for UCB banking market: Impact analysis
TABLE 5: Global market for UCB banking, by geography, 2010 – 2013 (USD million)
TABLE 6: Global market for UCB banking, by geography, 2014 – 2020 (USD million)
TABLE 7: Global market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 8: Global market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 9: Global market for UCB banking, by storage option, 2010 – 2013 (USD million)
TABLE 10: Global market for UCB banking, by storage option, 2014 – 2020 (USD million)
TABLE 11: Global market for therapeutic application of UCB in leukemia, by geography, 2010 – 2013 (USD million)
TABLE 12: Global market for therapeutic application of UCB in leukemia, by geography, 2014 – 2020 (USD million)
TABLE 13: Global market for therapeutic application of UCB in bone marrow failure syndrome, by geography, 2010 – 2013 (USD million)
TABLE 14: Global market for therapeutic application of UCB in bone marrow failure syndrome, by geography, 2014 – 2020 (USD million)
TABLE 15: Global market for therapeutic application of UCB in metabolic/storage diseases, by geography, 2010 – 2013 (USD million)
TABLE 16: Global market for therapeutic application of UCB in metabolic/storage diseases, by geography, 2014 – 2020 (USD million)
TABLE 17: Global market for therapeutic application of UCB in lymphoma, by geography, 2010 – 2013 (USD million)
TABLE 18: Global market for therapeutic application of UCB in lymphoma, by geography, 2014 – 2020 (USD million)
TABLE 19: Global market for therapeutic application of UCB in immune deficiencies, by geography, 2010 – 2013 (USD million)
TABLE 20: Global market for therapeutic application of UCB in immune deficiencies, by geography, 2014 – 2020 (USD million)
TABLE 21: Global market for private UCB banks, by geography, 2010 – 2013 (USD million)
TABLE 22: Global market for private UCB banks, by geography, 2014 – 2020 (USD million)
TABLE 23: Global market for public UCB banks, by geography, 2010 – 2013 (USD million)
TABLE 24: Global market for public UCB banks, by geography, 2014 – 2020 (USD million)
TABLE 25: The North American market for UCB banking, by country, 2010 – 2013 (USD million)
TABLE 26: The North American market for UCB banking, by country, 2014 – 2020 (USD million)
TABLE 27: The North American market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 28: The North American market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 29: The North American market for UCB banking, by storage option, 2010 – 2013 (USD million)
TABLE 30: The North American market for UCB banking, by storage option, 2014 – 2020 (USD million)
TABLE 31: The U.S. market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 32: The U.S. market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 33: Canada market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 34: Canada market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 35: The European market for UCB banking, by country, 2010 – 2013 (USD million)
TABLE 36: The European market for UCB banking, by country, 2014 – 2020 (USD million)
TABLE 37: The European market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 38: The European market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 39: The European market for UCB banking, by storage option, 2010 – 2013 (USD million)
TABLE 40: The European market for UCB banking, by storage option, 2014 – 2020 (USD million)
TABLE 41: The U.K. market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 42: The U.K. market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 43: French market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 44: French market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 45: German market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 46: German market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 47: Spanish market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 48: Spanish market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 49: Italian market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 50: Italian market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 51: Belgium market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 52: Belgium market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 53: Asia Pacific market for UCB banking, by country, 2010 – 2013 (USD million)
TABLE 54: Asia Pacific market for UCB banking, by country, 2014 – 2020 (USD million)
TABLE 55: Asia Pacific market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 56: Asia Pacific market for UCB banking, by therapeutic application, 2014 – 2020 (USD million)
TABLE 57: Asia Pacific market for UCB banking, by storage option, 2010 – 2013 (USD million)
TABLE 58: Asia Pacific market for UCB banking, by storage option, 2014 – 2020 (USD million)
TABLE 59: Chinese market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 60: Chinese market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 61: Indian market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 62: Indian market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 63: Japanese market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 64: Japanese market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 65: Australian market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 66: Australian market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 67: Singapore market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)
TABLE 68: Singapore market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)
TABLE 69: CBR major products and services categories
TABLE 70: Cordlife’s service categories
TABLE 71: CBAI’s product and services categories
TABLE 72: NeoStem’s major service categories
TABLE 73: Cryo-Cell’s service category
TABLE 74: ViaCord’s service categories
TABLE 75: Esperite’s major product and services categories
TABLE 76: StemCyte’s product and services categories
TABLE 77: Smart Cells’s service categories
TABLE 78: CCBC’s service category
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
List of Figures
FIG. 1: UCB banking market: Porter\'s five forces analysis
FIG. 2: Steps involved in UCB collection and banking
FIG. 3: Major therapeutic applications of UCB
FIG. 4: Global UCB banking market share, by region, by value, 2013
FIG. 5: Global UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 6: Global UCB banking market share, by storage option, by value, 2013
FIG. 7: Global therapeutic application of UCB for leukemia market share, by region, by value, 2013
FIG. 8: Global therapeutic application of UCB for bone marrow failure syndrome market share, by region, by value, 2013
FIG. 9: Global therapeutic application of UCB in metabolic/storage diseases market share, by region, by value, 2013
FIG. 10: Global therapeutic application of UCB for lymphoma market share, by region, by value, 2013
FIG. 11: Global therapeutic application of UCB for immune deficiencies market share, by region, by value, 2013
FIG. 12: Global private UCB banks market share, by region, by value, 2013
FIG. 13: Global public UCB banks market share, by region, by value, 2013
FIG. 14: The North American UCB banking market share, by country, by value, 2013
FIG. 15: The North American UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 16: The North American UCB banking market share, by storage option, by value, 2013
FIG. 17: The U.S. UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 18: Canada UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 19: The European UCB banking market share, by country, by value, 2013
FIG. 20: The European UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 21: The European UCB banking market share, by storage option, by value, 2013
FIG. 22: The U.K. UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 23: French UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 24: German UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 25: Spanish UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 26: Italian UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 27: Belgium UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 28: Asia Pacific UCB banking market share, by country, by value, 2013
FIG. 29: Asia Pacific UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 30: Asia Pacific UCB banking market share, by storage option, by value, 2013
FIG. 31: Chinese UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 32: Indian UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 33: Japanese UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 34: Australian UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 35: Singapore UCB banking market share, by therapeutic application of UCB, by value, 2013
FIG. 36: Competitive landscape of UCB banking market
FIG. 37: Cordlife revenue and profit, 2012 – 2014 (USD million)
FIG. 38: CBAI revenue and net loss/income, 2011 – 2013 (USD million)
FIG. 39: NeoStem revenue and net loss/income, 2011 – 2013 (USD million)
FIG. 40: Cryo-Cell revenue and net loss/income, 2011 – 2013 (USD million)
FIG. 41: Esperite’s revenue and profit, 2011 – 2013 (USD million)
FIG. 42: CCBC’s revenue and net income, 2012 – 2014 (USD million)
